Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares Outstanding
Ratios

Eledon Pharmaceuticals (ELDN) EBIAT (2016 - 2026)

Eledon Pharmaceuticals filings provide 5 years of EBIAT readings, the most recent being -$2.1 million for Q4 2017.

  • On a quarterly basis, EBIAT rose 43.54% to -$2.1 million in Q4 2017 year-over-year; TTM through Dec 2017 was -$13.1 million, a 27.93% increase, with the full-year FY2025 number at -$45.6 million, down 26.07% from a year prior.
  • EBIAT hit -$2.1 million in Q4 2017 for Eledon Pharmaceuticals, up from -$3.0 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of -$1.0 million in Q2 2016 to a low of -$13.3 million in Q1 2015.
  • Median EBIAT over the past 5 years was -$5.7 million (2013), compared with a mean of -$6.0 million.
  • Biggest five-year swings in EBIAT: surged 88.81% in 2016 and later tumbled 564.87% in 2017.
  • Eledon Pharmaceuticals' EBIAT stood at -$5.5 million in 2013, then fell by 12.36% to -$6.2 million in 2014, then tumbled by 77.46% to -$11.0 million in 2015, then skyrocketed by 66.08% to -$3.7 million in 2016, then skyrocketed by 43.54% to -$2.1 million in 2017.
  • The last three reported values for EBIAT were -$2.1 million (Q4 2017), -$3.0 million (Q3 2017), and -$6.7 million (Q2 2017) per Business Quant data.